771 related articles for article (PubMed ID: 23032417)
1. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
2. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.
Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I
Clin Infect Dis; 2011 Jan; 52(1):128-37. PubMed ID: 21148531
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
4. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
Mallory RM; Yi T; Ambrose CS
Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
[TBL] [Abstract][Full Text] [Related]
7. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
8. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
Beran J; Vesikari T; Wertzova V; Karvonen A; Honegr K; Lindblad N; Van Belle P; Peeters M; Innis BL; Devaster JM
J Infect Dis; 2009 Dec; 200(12):1861-9. PubMed ID: 19909082
[TBL] [Abstract][Full Text] [Related]
10. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
Rhorer J; Ambrose CS; Dickinson S; Hamilton H; Oleka NA; Malinoski FJ; Wittes J
Vaccine; 2009 Feb; 27(7):1101-10. PubMed ID: 19095024
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
16. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.
Andrews N; McMenamin J; Durnall H; Ellis J; Lackenby A; Robertson C; von Wissmann B; Cottrell S; Smyth B; Moore C; Gunson R; Zambon M; Fleming D; Pebody R
Euro Surveill; 2014 Jul; 19(27):5-13. PubMed ID: 25033051
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B;
Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
